<DOC>
	<DOCNO>NCT01763788</DOCNO>
	<brief_summary>The purpose Phase 1b portion study investigate body tolerates necitumumab , combination gemcitabine cisplatin chemotherapy first line treatment participant Stage IV squamous NSCLC determine recommend dose subsequent Phase 2 portion study . The purpose Phase 2 portion study evaluate efficacy necitumumab combination gemcitabine cisplatin chemotherapy participant Stage IV squamous NSCLC first-line setting .</brief_summary>
	<brief_title>A Study Necitumumab First-Line Treatment Stage IV Squamous Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Squamous NonSmall Cell Lung Cancer Disease Clinical Stage IV Measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 No prior chemotherapy regimen , surgery chest radiotherapy Adequate organ function Estimated life expectancy least 12 week Has undergone major surgery within 28 day prior enrollment plan major surgery , subcutaneous venous access device placement within 7 day prior enrollment Has undergone prior radiation therapy , except Gamma Knife radiation palliative radiation treatment least 14 day elapse last radiation treatment prior enrollment Has brain metastasis symptomatic require surgery , medication radiotherapy except Gamma Knife Has superior vena cava syndrome Has clinically relevant coronary artery disease uncontrolled congestive heart failure Has uncontrolled hypertension Has diabetes require insulin Has angina experience myocardial infarction within 6 month prior enrollment Has Acquired Immunodeficiency Syndrome ( AIDS ) relate illness Has evidence test positive test result hepatitis B , hepatitis C virus antibody Has know allergy history hypersensitivity reaction Has significant thirdspace fluid retention Has history interstitial pneumonitis Has ongoing active infection Has history significant neurological psychiatric disorder Has Grade 2 peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>